

Do you have Neurotrophic Keratopathy?

Requirements:

Must be 18 years or older.

Have stage 2 or 3 Neurotrophic Keratopathy in at least one eye.

Additional criteria may apply so that need to discuss this with your eye doctor.

Who is the Sponsor?

ReGenTree, LLC is a U.S. joint venture company owned by HLB Therapeutics Co. Ltd., a biotech company in Korea and RegeneRx Biopharmaceuticals, Inc., a clinical stage drug development company in the U.S.

ReGenTree is developing a novel therapeutic peptide, RGN-259, in the U.S. and Canada for ophthalmic indications.

Contact Information

Please contact your referring Ophthalmologist or view the below contact information and link to find a participating site nearest your location.

Ted Um, ReGenTree, LLC. Director of Clinical Operation

Phone: +1 609-734-4328

Email: ted@regentreeinc.com

Study Information

ClinicalTrials.gov Identifier (NCT#): NCT05555589



We are looking for you

Finding Treatments Together for Neurotrophic Keratopathy (NK)

SEER-2 is a clinical study to assess the safety and efficacy of Thymosin β 4 Ophthalmic Solution (RGN-259) for the treatment of Neurotrophic Keratopathy (NK). The study will enroll approximately 70 patients with chronic stage 2 and 3 NK in 35 sites in the U.S.

A clinical research study for NK is enrolling now.

- Only 4 weeks treatment + 2 weeks follow up
- No-cost investigational medication
- Compensation may be provided
- Just 5 drops/day for treatment

• **SEER-2:** Safety and Efficacy Examination of RGN-259



Neurotrophic Keratopathy

- NK is degenerative corneal disease resulting loss of corneal sensitivity
- Patients with NK develop poorly-healing, recurrent corneal abrasions or defects that are slow to respond to current therapies.
- Not usually feel pain due to the damaged cornea nerves

What is RGN-259?

RGN-259 Ophthalmic Solution

Most Advanced, Preservative-Free, Single Unit Dose, formulated as Thymosin beta 4 eye drops for the treatment of both dry eye disease (DED) and neurotrophic keratopathy (NK).

Clinical Trials

- 10 completed ophthalmic and dermal studies:
- RGN-259 has clinically significant effects on NK disease by many studies.
- No significant Adverse effects and no clinically significant changes in any safety parameters were found

Good opportunity

- Potentially Fast healing
- Safe and well-tolerated confirmed by previous clinical studies.

Study Visit plan

Study Duration

- Total 6 weeks: 4 weeks Treatment + 2 weeks Post-Treatment Follow-Up

Visit Schedule

